Sarepta Therapeutics Settles AAVrh74 Patent Disputes With REGENXBIO and UPenn for $39 Million

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO and the University of Pennsylvania to resolve patent disputes related to AAVrh74-based gene therapies, including ELEVIDYS. Sarepta will pay a $39 million lump sum and receive broad releases and covenants not to sue covering spe…